Survival

Drug cocktail may extend life in inoperable hepatocellular carcinoma

Published in Hepatitis Weekly, April 15th, 2002

by Sonia Nichols, senior medical writer - In cases where surgery cannot be performed for primary liver cancer, combination therapy that includes four well-known drugs may extend survival.

Due to various reasons, patients with hepatocellular carcinoma (HCC), a primary form of liver cancer, are not always good candidates for tumor resection. Doctors in Hong Kong are now recommending that in those instances, systemic therapy consisting of a combination of cisplatin, interferon (IFN)-(alpha), doxorubicin, and 5-fluorouracil, also known as PIAF, may be sufficient for extending patient survival, particularly in those whose bilirubin levels remain low and who do not have...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2002-04-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry